President Trump The executive order signed On Tuesday, he identified a series of measures aimed at lowering the prices of drugs, including helping countries to import medicines from Canada.
Policies were more modest than proposals to reduce the prices of drugs presented by Mr. Trump in his first term.
One of his new directives can increase drug prices. The Trump administration calls to work with Congress to change the 2022 Law in a way that can spoil the negotiating program that aims to reduce Medicare’s spending on common or expensive drugs.
Such a change has the ability to increase government costs, because it is likely that the current schedule of some medications is likely to be delayed to be eligible to reduce medical care prices.
Depending on how it is organized, it can increase drug spending in Medicare by billions of dollars compared to fireworks under the current law. The negotiating program was approved by a conference controlled by Democrats and supported by former President Joseph R. Biden Junior.
The executive thing says that the changes in the program to negotiate the prices of medical care must be “associated with other reforms to prevent any increase in the total costs of medical care and its beneficiaries.”
With the exception of the proposal to negotiate medical care, other directives in the executive order have the ability to save money for patients and government programs. None of the procedures represented major changes that would lead to huge savings.
One of the rulings reduces the joint payments that some people face on medical care when they are undergoing treatments such as chemotherapy batches in some clinics and external hospital sites. Another would give some low -income people to access insulin injection and dramatically reduced albinifrin.
On Tuesday, the executive was the most prominent step that Mr. Trump’s second administration has taken on drug prices.
After Mr. Trump’s decision to approach the imposition of definitions on imported drugs, which manufacturers are likely to try to transfer. This can force government programs, employers and patients to pay more against some medications and may exacerbate the deficiency of critical drugs.
Some directions, such as changing the negotiating program on medical care, will require congressional approval. The pharmaceutical industry strongly opposed some ideas on the executive matter with the support of others.
Mr. Trump has a long Complain The United States pays much more than other wealthy countries for the same drugs. It was noticeably absent from the regime as a policy of pricing the most preferred nation, which he proposed in its first term that aims to make the prices of medicines closer to those paid by peer countries. Like many of the first policies of Mr. Trump on drug prices, federal courts have stopped the most preferred nation plan. Last fall, Mr. Trump’s presidential campaign went on the proposal.
Below is a collapse of some of the most famous parts of Mr. Trump’s executive order.
Eliminating “the penalty for birth control”
Robert F. Kennedy Junior, Minister of Health, to work with Congress to address the difference in how to treat certain types of medications in the negotiating medical care program.
Under the law, birth control pills and other drugs that are produced through artificial processes do not become qualified to reduce prices until they are on the market for a period of nine years. Medicines known as biology – created from live cells and are often given as signs – will not be qualified for 13 years.
Medicines, who filed a lawsuit against the federal government in vain, fire the bitterness of the teams “a pill penalty.” They say they discourage them from developing medications, because they have less time to build sales before the price cuts begin, and to deprive patients of new treatments. They pressed the exemption of birth control pills from price cuts for 13 years instead of nine.
Legislators Presented Legislation would change the law to treat two types of equality.
The president’s order does not specify the number of years that must be exempted from each type of drug from the reduction of medical care prices.
Biden officials supervised the first round of negotiations in the program, which led to discounts in prices that will enter into force in 2026. The Trump administration supervised the negotiations this year because of the decrease in prices in 2027 for drugs, including drugs that are sold in the sponsorship of the sponsorship that was sold as the Azmbek and Muhawfi.
White House He said in the fact paper on Tuesday She wanted to get more savings for the government through the program to negotiate more medical care than the Biden administration last year. It will be difficult to do this if Congress reduces the time when you can get lower prices.
Importing medicines from Canada
The executive order directs the Food and Drug Administration to improve Process Through which countries can apply to the import of low -cost drugs from Canada.
In his first term, Mr. Trump It created a path Enabling countries to follow these imports. Under the Biden Administration, the FDA approved a single import program in Florida. As of late last year, Florida was It has not started yet Import medications from Canada. The drug industry opposes the idea because it will reduce its profits.
If Mr. Trump is followed by imposing a customs tariff on medicines, it is unlikely that the import of medicines from Canada is likely to provide the same savings as in the past.
A different subscriber in different clinics
The request calls for rules for equal fees that doctors are paid to manage medicines to patients via settings.
Currently, many hospital -owned medical practices can impose higher fees on medical care than independent practices, even for exact services themselves. Since the beneficiaries of medical care are often responsible for a percentage of their medical bills, these higher costs are passed in the form of joint payments.
The efforts to achieve equality of such payments were widely in discussion from the two parties for years in Congress but faced opposition from hospitals, who say they need higher payments. The legislation approved during the Obama administration took some of these differences in payment.
Encourage cheaper copies
Mr. Trump has ordered the Food and Drug Administration to provide recommendations to simplify approvals for public drugs and biological drugs, which are low -pricing copies of biological drugs.
The first BIOSIMIRAR was approved in 2015, with more than dozens of approval since then. There was widespread hope that biological biologists protected patents, such as HUMIA for conditions such as arthritis, which led to high costs of the drug. But the patients were slow to switch, and the savings were not achieved at the speed that many wanted.
Insulin for the poor
Mr. Trump revived a Executive order From his first term that community health clinics direct to providing insulin and ibenifrin injections at very reduced prices for some low -income persons, including the unbelievable.
The clinics swollen when Mr. Trump suggested the idea in 2020.